Subchronic administration of LY354740 does not modify ketamine-evoked behavior and neuronal activity in rats

Gabor Imre*, Dirk S. Fokkema, Gert J. Ter Horst

*Bijbehorende auteur voor dit werk

    OnderzoeksoutputAcademicpeer review

    19 Citaten (Scopus)

    Samenvatting

    Acute treatment with LY354740 {1S,2S,5R,6S-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylate monohydrate}, a potent and selective agonist for group 11 metabotropic glutamate receptors (mGlu2/3), has previously been shown to block some schizophrenia-like effects of N-methyl-D-aspartate (NMDA) receptor antagonists, suggesting a novel therapeutic strategy for schizophrenia. The present study examined the effects of subchronic pretreatment with LY354740 (0.3, 3 and 10 mg/kg i.p.) on ketamine-evoked (12 mg/kg s.c.) prepulse inhibition deficits, hyperlocomotion and c-fos expression. At all doses, LY354740 failed to reverse both behavioral and neuronal effects of the ketamine. These results therefore do not support the putative antipsychotic role of LY354740. (c) 2006 Elsevier B.V All rights reserved.

    Originele taal-2English
    Pagina's (van-tot)77-81
    Aantal pagina's5
    TijdschriftEuropean Journal of Pharmacology
    Volume544
    Nummer van het tijdschrift1-3
    DOI's
    StatusPublished - 21-aug-2006

    Citeer dit